HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...
Vous n'êtes pas connecté
Vimgreen Pharmaceuticals, a science─driven pharmaceutical company focused on the modulation of adenosine signalling, announced the completion of enrollment of its phase 2 clinical trial of VG081821AC, a
HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...
NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024. Rigel Pharmaceuticals, a commercial stage biotechnology company focused on hematologic disorders and...
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Cytovation ASA, a clinical stage oncology company focused on the development of its first─in─class bifunctional immunotherapy CY─101 (CyPep─1)...
Interstitial Lung Disease Clinical Trials Interstitial Lung Disease companies are AstraZeneca, CSL Behring, Syndax Pharmaceuticals, Taiho...
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional...
LEIDEN, Netherlands, Sept. 13, 2024. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological...
Nxera Pharma Co., Ltd.(formerly known as Sosei Group or Sosei Heptares), announces that it will receive a US$ 35 million payment from Neurocrine...